Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer

PURPOSE: To compare the prostate-specific antigen (PSA) relapse-free survival outcome and incidence of late toxicity for patients with early-stage prostate cancer treated at a single institution with either three-dimensional conformal radiotherapy (3D-CRT) or transperineal permanent implantation (TPI) with iodine-125 seeds. MATERIALS AND METHODS: Patients with favorable-risk prostate cancer, defined as a pretreatment PSA of less than or equal to 10.0 ng/mL, Gleason score of 6 or lower, and stage less than or equal to T2b, were selected for this analysis. Between 1989 and 1996, 137 such patients were treated with 3D-CRT and 145 with TPI. The median ages of the 3D-CRT and TPI groups were 68 years and 64 years, respectively. The median dose of 3D-CRT was 70.2 Gy, and the median implant dose was 150 Gy. Prostate-specific antigen relapse was defined according to the American Society of Therapeutic Radiation Oncology Consensus Statement, and toxicity was graded according to the Radiation Therapy Oncology Group ...

[1]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[2]  M. Zelefsky,et al.  Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. , 1994, International journal of radiation oncology, biology, physics.

[3]  R. Stock,et al.  The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, Seminars in surgical oncology.

[4]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[5]  R Mohan,et al.  Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. , 1996, International journal of radiation oncology, biology, physics.

[6]  R. Stock,et al.  Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. , 1996, International journal of radiation oncology, biology, physics.

[7]  W Cavanagh,et al.  Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. , 1997, Seminars in surgical oncology.

[8]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[9]  J Roy,et al.  Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[10]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[11]  P. Rubin,et al.  Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. , 1991, International journal of radiation oncology, biology, physics.

[12]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[13]  J. Roy,et al.  Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. , 1995, International journal of radiation oncology, biology, physics.

[14]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[15]  G J Kutcher,et al.  Three-dimensional conformal radiotherapy and dose escalation: where do we stand? , 1998, Seminars in radiation oncology.

[16]  J Roy,et al.  Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.

[17]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[18]  D. Cox.  Regression Models and Life-Tables , 1972 .

[19]  H. Levin,et al.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.

[20]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[21]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Roy,et al.  CT-based optimized planning for transperineal prostate implant with customized template. , 1991, International journal of radiation oncology, biology, physics.